Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model.
Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and immunological pathways may be responsible for such an insensitivity. Our findings suggest that a combination of targeted anticancer agents and immunomodulatory drugs may be useful for overcoming the acquired resistance of cancer cells to EGFR-specific monoclonal antibodies.
Tumor Immunology Direction; Molecular Immunology Institute; Center of Molecular Immunology; Havana, Cuba.
Greta
G
Garrido
Tumor Immunology Direction; Molecular Immunology Institute; Center of Molecular Immunology; Havana, Cuba.
Ailem
A
Rabasa
Tumor Immunology Direction; Molecular Immunology Institute; Center of Molecular Immunology; Havana, Cuba.
Belinda
B
Sánchez
EGFR; MHCI alterations; acquired resistance; monoclonal antibodies